Adaptive Biotechnologies (ADPT) Price Target Raised by Piper Sandler | ADPT Stock News

Author's Avatar
May 06, 2025
Article's Main Image

On May 6, 2025, Piper Sandler analyst David Westenberg announced a revised price target for Adaptive Biotechnologies (ADPT, Financial). The price target was increased from $11.00 to $13.00, reflecting an 18.18% change. This adjustment indicates a positive outlook on the company’s stock performance.

Adaptive Biotechnologies (ADPT, Financial) continues to receive an "Overweight" rating from Piper Sandler, maintaining its previous assessment. The "Overweight" rating suggests that the analyst expects the stock to perform better than the average market return in the upcoming period.

The revised price target and sustained "Overweight" rating underscore confidence in Adaptive Biotechnologies' (ADPT, Financial) growth prospects, suggesting potential value for investors at the newly adjusted price point.

Wall Street Analysts Forecast

1919795867519447040.png

Based on the one-year price targets offered by 6 analysts, the average target price for Adaptive Biotechnologies Corp (ADPT, Financial) is $11.33 with a high estimate of $13.00 and a low estimate of $9.00. The average target implies an upside of 13.11% from the current price of $10.02. More detailed estimate data can be found on the Adaptive Biotechnologies Corp (ADPT) Forecast page.

Based on the consensus recommendation from 8 brokerage firms, Adaptive Biotechnologies Corp's (ADPT, Financial) average brokerage recommendation is currently 1.9, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.

Based on GuruFocus estimates, the estimated GF Value for Adaptive Biotechnologies Corp (ADPT, Financial) in one year is $8.38, suggesting a downside of 16.37% from the current price of $10.02. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Adaptive Biotechnologies Corp (ADPT) Summary page.

Disclosures

I/We may personally own shares in some of the companies mentioned above. However, those positions are not material to either the company or to my/our portfolios.